Kiniksa Pharmaceuticals Stock Investor Sentiment
| KNSA Stock | USD 22.08 0.24 1.08% |
About 67% of Kiniksa Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Kiniksa Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Kiniksa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kiniksa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Kiniksa |
Kiniksa Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Kiniksa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Kiniksa Pharmaceuticals that are available to investors today. That information is available publicly through Kiniksa media outlets and privately through word of mouth or via Kiniksa internal channels. However, regardless of the origin, that massive amount of Kiniksa data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kiniksa Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kiniksa Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kiniksa Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kiniksa Pharmaceuticals alpha.
Kiniksa Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 10000 shares by Eben Tessari of Kiniksa Pharmaceuticals at 1.59 subject to Rule 16b-3 | 09/23/2024 |
2 | Disposition of 1994 shares by John Paolini of Kiniksa Pharmaceuticals at 26.74 subject to Rule 16b-3 | 09/30/2024 |
3 | Acquisition by Sanj Patel of 6569 shares of Kiniksa Pharmaceuticals subject to Rule 16b-3 | 10/01/2024 |
4 | Acquisition by Baker Bros. Advisors Lp of 28384 shares of Kiniksa Pharmaceuticals at 24.48 subject to Rule 16b-3 | 10/04/2024 |
5 | Kiniksa Pharmaceuticals International PLC Shares Up 3.11 percent on Oct 22 | 10/22/2024 |
6 | Heres What Could Help Kiniksa Pharmaceuticals Maintain Its Recent Price Strength | 10/28/2024 |
7 | Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution | 10/29/2024 |
8 | Kiniksa Pharmaceuticals International PLC Q3 2024 Earnings Call Highlights Impressive ... | 10/30/2024 |
9 | Kiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts | 11/01/2024 |
10 | Kiniksa Pharmaceuticals Given New 40.00 Price Target at JPMorgan Chase Co. | 11/05/2024 |
11 | Disposition of 89561 shares by Sanj Patel of Kiniksa Pharmaceuticals at 1.59 subject to Rule 16b-3 | 11/06/2024 |
12 | Disposition of 1303 shares by Levy Richard S of Kiniksa Pharmaceuticals subject to Rule 16b-3 | 11/07/2024 |
13 | Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference | 11/12/2024 |
14 | Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference | 11/26/2024 |
Complementary Tools for Kiniksa Stock analysis
When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |